Chayora Breaks Ground on First of Two Hyperscale Data Centre Campuses in China
Project Marks the Initial Phase of a USD $2 Billion Investment Programme
HONG KONG, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Chayora Limited, a Hong Kong-based data centre infrastructure company, announces today it has finalised agreements with the government of Beichen, Tianjin, to begin construction of the company's first hyperscale data centre campus in China. The 300MW, 32-hectare / 80-acre campus will serve the greater Beijing region that is home to more than 150 million people in the JingJinJi mega-metropolitan area of northern China.
Commencing the first phase of development of Chayora's initial data centre building, construction is already underway with a completion and live operations target date of the end of 2018. This first building on Chayora's Tianjin Data Centre campus is designed for up to full 2N resilience and redundancy with dedicated substations for a 25MW IT load. Both gas turbine power generation and advanced grid power will support the site.
Chayora is leveraging industry-leading, prefabricated modular data centre design and construction that will enable world-class standards to be delivered quickly and to precisely assured tolerances while providing companies with flexible capacity growth options as more international businesses begin to expand in China.
The Chayora Tianjin campus, when completely built-out, will comprise six large 3000 rack data centres and three smaller 1000 rack high performance computing facilities. Each will be tailored to meet international enterprise or colocation operators' design and operational standards within an agreed masterplan and flexible building configurations. Assured scalability from 2MW to 100MW+ and full turnkey financed solutions are a core feature of Chayora customer agreements.
"The continued development of China and its importance to the global economy was underlined by China's leadership at the 19th National People's Congress in Beijing in October," says Oliver Jones, co-founder and Chief Executive Officer, Chayora. "The creation of world-class technology infrastructure will play a key part in underpinning these goals and Chayora is committed to supporting this achievement. Recent predictions from Forward Intelligence Group indicate that China will represent approximately 25 percent of world cloud revenues by 2020. This aligns with our own expectations and reinforces our strategy of creating some of the world's largest and most advanced data centre sites to accommodate these developments."
Forthcoming in the second quarter of 2018, Chayora will begin construction of its second hyperscale campus, a 280MW data centre to serve the greater Shanghai region. Unlike most other options for Shanghai, Chayora's facilities will be newly-built and designed from the ground up to international standards with all necessary permits to enable global corporates to access Shanghai and the surrounding provinces of eastern China, a population of more than 200 million. Shanghai is a key location for global organisations, including financial services, e-commerce and cloud service providers, and is in need of significant high performance data centre capacity.
Chayora's core offering is to develop and operate large-scale, built-to-suit, high-performance data centres for individual clients on long-term contracts across multiple strategically-located campuses, complete with ready-to-operate, robust and scalable infrastructure capable of supporting world-class data centre operational standards. Chayora is also raising further investment resources to augment its existing capital, and to pursue its plan to design and build additional data centre campuses in key connectivity hubs across China.
For more information about Chayora, visit www.chayora.com.
Chayora Limited, headquartered in Hong Kong, is wholly-owned by Chayora Holdings Limited, a Cayman Island-based company. Chayora develops large-scale, world-class designed and operated, long-term scalable data centres and data centre campuses in China. Chayora serves global Fortune 500 companies and premium Chinese data centre users offering cloud services, ICT services, financial services or other services offerings relying on intensive, high quality data centre infrastructure in China.
|Media Relations Enquiries:|
|Oliver Jones||Jonathan Berney|
|+852 9227 3850 / +44 7802 985053||+852 9223 1446 / +852 2297 2202|
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Chayora Limited via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress25.5.2018 07:45 | Pressemelding
CALGARY, Alberta, May 24, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Friday, May 25, 2018, at the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress in Copenhagen, Denmark, the Company is supporting a symposium titled: "Epigenetics in CKD & CVD: A potential breakthrough therapy?" The symposium highlights the role of epigenetics and BET-inhibition in chronic kidney disease and cardiovascular disease, especially in patients with diabetes mellitus, and the significant unmet need that still exists in this patient population. The symposium is co-chaired by Vincent M. Brandenburg, MD - Nephrologist, Aachen, Germany and Kamyar Kalantar-Zadeh, MD - UC Irvine School of Medicine, Irvine, CA, USA, both leading scientists also serving as advisors to Resverlogix's Renal program. The speakers and agenda are as follows: Introduction Vincent M. Brandenburg, MD - University Hospital of the RWTH
Atico Reports Consolidated Financial Results for the First Quarter of 201824.5.2018 22:30 | Pressemelding
(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, May 24, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSX.V:ATY) (OTC:ATCMF) today announced its financial results for the three months ended March 31, 2018, posting a net income of $0.4 million. Fernando E. Ganoza, CEO and Director, commented, "The strong production and all-in sustaining cash cost of $1.85 achieved this quarter is not reflected in the financial results as a large concentrate shipment was delayed to the second quarter, along with the revenue associated with those tonnes. The shipping schedule is expected to stabilize during the second quarter, where we will then benefit from the additional shipped concentrate and recognized revenue. We anticipate strong financial results in the next quarter." Mr. Ganoza continued, "Our emphasis will continue to be on further strengthening our balance sheet, improving production costs and most importantly regional
Luxembourg Announced as SNOMED International's Newest Member24.5.2018 15:16 | Pressemelding
London, United Kingdom, May 24, 2018 (GLOBE NEWSWIRE) -- SNOMED International and Agence eSanté Luxembourg are pleased to announce that Luxembourg has joined the organization as its thirty-second Member. Luxembourg, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority. Agence eSanté, Luxembourg's national agency for the exchange and sharing of medical data, has set an overall mission to facilitate clinical information exchange both within Luxembourg and across other international actors. To work towards this reality, the agency has taken part in discussions about standardization across Europe, a contributing building block achieved with its membership in SNOMED International. With their membership, Agence eSanté has committed their support for the use of structured clinical terminology. When applied to the health sector, interoperability ensures that information systems, and through them h
SEMAFO Signs Underground Mining Services Contract with AUMS24.5.2018 14:00 | Pressemelding
MONTREAL, May 24, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports that it has signed a mining services contract with African Underground Mining Services ("AUMS") to provide turnkey mining services for Siou underground. AUMS is a well-known and reputable mining contractor with underground experience in Burkina Faso and across Africa. Under the mining services contract, AUMS will be responsible for supplying the mining fleet and a skilled labour force for Siou underground in addition to ensuring development, production and auxiliary services. SEMAFO will provide technical services including geology and engineering as well as leveraging the existing surface infrastructure at Mana. The mining services contract has a term of 70 months. The economic terms of the mining services contract are consistent with the economics presented in the Mana pre-feasibility study filed March 29, 2018 on SEDAR. Preparatory work has already commenced on Siou underground with full project deplo
Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors24.5.2018 13:00 | Pressemelding
- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018. With this acceptance, Merus plans to open additional sites for this trial in the United States. MCLA-158 is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal grow
PRA Named International Clinical Research Company of the Year24.5.2018 10:00 | Pressemelding
RALEIGH, N.C., May 24, 2018 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ:PRAH) is pleased to announce it was recognized by PharmaTimes as the International Clinical Research Company of the Year. This is the fifth year in a row that PRA has received this award. "This award celebrates excellence in the clinical research industry and we are honored to once again be recognized by our peers," said Colin Shannon, President and Chief Executive Officer. "This award is possible thanks to the incredibly talented PRA team members we have working around the world who are deeply committed to their work in bringing new and life-saving therapies to the patients who need them." PRA also swept the Clinical Research Associate and Clinical Trial Administrator categories capturing a total of 11 awards. These awards follow PRA's recognition earlier this month in the PharmaTimes Americas competition where PRA also received 11 awards, including Company of the Year. The PharmaTimes, International Cli
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom